MDACC Study No:2012-0569 ( NCT No: NCT01657682)
Title:A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients with FLT3 Activating Mutations
Principal Investigator:Jorge Cortes
Treatment Agent:Crenolanib
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if crenolanib can help to
control FLT3 mutated AML that has gotten worse.

Crenolanib is designed to block the FLT3 gene mutation, which may kill the
leukemia cells.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Crenolanib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:AROG Pharmaceuticals, LLC
Leukemia SPORE
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults